Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $7.02 and traded as low as $6.58. Titan Pharmaceuticals shares last traded at $6.82, with a volume of 1,686 shares.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Titan Pharmaceuticals in a research report on Thursday. They set a “sell” rating on the stock.
Read Our Latest Analysis on TTNP
Titan Pharmaceuticals Price Performance
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- The Most Important Warren Buffett Stock for Investors: His Own
- Generac Powers Ahead on the Electrification Mega-Trend
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.